Compare SCWO & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SCWO | IMUX |
|---|---|---|
| Founded | 2021 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Environmental Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 72.8M | 85.8M |
| IPO Year | N/A | N/A |
| Metric | SCWO | IMUX |
|---|---|---|
| Price | $0.23 | $0.59 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 1.2M | ★ 1.4M |
| Earning Date | 11-12-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $1,910,340.00 | N/A |
| Revenue This Year | $5,945.19 | N/A |
| Revenue Next Year | $106.82 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 508.52 | N/A |
| 52 Week Low | $0.16 | $0.55 |
| 52 Week High | $1.09 | $1.39 |
| Indicator | SCWO | IMUX |
|---|---|---|
| Relative Strength Index (RSI) | 40.79 | 38.15 |
| Support Level | $0.22 | $0.55 |
| Resistance Level | $0.27 | $0.65 |
| Average True Range (ATR) | 0.03 | 0.04 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 38.49 | 22.84 |
374Water Inc offers a technology that transforms wet wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, and forever chemicals (e.g., PFAS) into recoverable resources by focusing on waste as a valuable resource for water, energy, and minerals. The company's business activities include manufacturing processes and waste recycling and treatment processes, which currently involve the use, treatment, storage, transfer, handling and/or disposal of hazardous materials, chemicals and wastes.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.